Edition:
United Kingdom

Koninklijke DSM NV (DSMN.AS)

DSMN.AS on Amsterdam Stock Exchange

91.96EUR
22 Feb 2019
Change (% chg)

€1.20 (+1.32%)
Prev Close
€90.76
Open
€91.00
Day's High
€92.58
Day's Low
€90.94
Volume
662,336
Avg. Vol
826,701
52-wk High
€96.38
52-wk Low
€68.00

Chart for

About

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company's segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties. Its Performance... (more)

Overall

Beta: 0.83
Market Cap(Mil.): €12,599.97
Shares Outstanding(Mil.): 181.43
Dividend: 0.58
Yield (%): 2.56

Financials

  DSMN.AS Industry Sector
P/E (TTM): 16.53 15.40 325.77
EPS (TTM): 4.20 -- --
ROI: 5.62 7.49 10.50
ROE: 13.12 11.78 13.69

DSM sets up vitamin E joint venture with China's Nenter

AMSTERDAM DSM NV, the Dutch nutrition company, said on Tuesday it would set up a joint venture with Chinese biochemicals company Nenter & Co. to manufacture vitamin E, paying Nenter 135 million euros ($154.45 million) to acquire its facilities in China.

29 Jan 2019

DSM sets up vitamin E joint venture with China's Nenter

AMSTERDAM, Jan 29 DSM NV, the Dutch nutrition company, said on Tuesday it would set up a joint venture with Chinese biochemicals company Nenter & Co. to manufacture vitamin E, paying Nenter 135 million euros ($154.45 million) to acquire its facilities in China.

29 Jan 2019

UPDATE 1-DSM Q3 core profit rises 11 pct on higher vitamin prices

AMSTERDAM, Oct 31 Dutch speciality chemicals company DSM on Wednesday beat analyst expectations with an 11-percent rise in third-quarter core profit, to 406 million euros ($460.4 million), helped by elevated vitamin prices and higher sales.

31 Oct 2018

DSM Q3 core profit rises 11 pct on higher vitamin prices

AMSTERDAM, Oct 31 Dutch speciality chemicals company DSM on Wednesday beat analyst expectations with an 11-percent rise in third-quarter core profit, to 406 million euros ($460.4 million), helped by elevated vitamin prices and higher sales.

31 Oct 2018

Earnings vs. Estimates